Main public logs
Jump to navigation
Jump to search
Combined display of all available logs of wikidoc. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).
- 01:53, 8 May 2024 Edzelco talk contribs created page File:LOQTORZI Dosage.png
- 01:53, 8 May 2024 Edzelco talk contribs uploaded File:LOQTORZI Dosage.png
- 08:08, 17 April 2024 Edzelco talk contribs created page Elranatamab-bcmm (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:08, 17 April 2024 Edzelco talk contribs created page Palovarotene (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:08, 17 April 2024 Edzelco talk contribs created page Pozelimab-bbfg (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:07, 17 April 2024 Edzelco talk contribs created page Motixafortide (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:07, 17 April 2024 Edzelco talk contribs created page Momelotinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:06, 17 April 2024 Edzelco talk contribs created page Cipaglucosidase alfa-atga (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:05, 17 April 2024 Edzelco talk contribs created page Etrasimod (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:05, 17 April 2024 Edzelco talk contribs created page Zilucoplan (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Bimekizumab (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Vamorolone (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:04, 17 April 2024 Edzelco talk contribs created page Mirikizumab-mrkz (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:03, 17 April 2024 Edzelco talk contribs created page Toripalimab-tpzi (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}")
- 08:02, 17 April 2024 Edzelco talk contribs created page Fruquintinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...")
- 07:52, 17 April 2024 Edzelco talk contribs created page Taurolidine, heparin (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...")
- 07:43, 17 April 2024 Edzelco talk contribs created page Repotrectinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...")
- 07:32, 17 April 2024 Edzelco talk contribs created page Efbemalenograstim alfa-vuxw (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....")
- 05:50, 16 April 2024 Edzelco talk contribs created page Capivasertib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...")
- 05:27, 16 April 2024 Edzelco talk contribs created page Iptacopan (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...")
- 07:24, 15 April 2024 Edzelco talk contribs created page Vutrisiran (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj...")
- 22:23, 11 February 2024 Edzelco talk contribs created page Mavacamten (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=mavacamten |aOrAn=a |drugClass=cardiac myosin inhibitor |indicationType=treatment |indication=adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms |hasBlackBoxWarning=Yes |adverseReactions=dizziness (27%) and syncope (6%) |blackBoxWarningTitle=WARNING: RISK OF HEART...")
- 19:04, 10 February 2024 Edzelco talk contribs created page Oteseconazole (Created page with "{{DrugProjectFormSinglePage |genericName=oteseconazole |aOrAn=an |drugClass=azole antifungal |indicationType=prevention |indication=recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential |adverseReactions=headache and nausea |fdaLIADAdult=VIVJOA Capsules: 150 mg of oteseconazole in lavender hard gelatin capsules imprinted with OTE 150 in black ink. Fluconazole is not supplied in the carton. |co...")
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label3.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label3.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label2.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label2.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA label.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA label.png
- 19:02, 10 February 2024 Edzelco talk contribs created page File:VIVJOA structure.png
- 19:02, 10 February 2024 Edzelco talk contribs uploaded File:VIVJOA structure.png
- 00:47, 7 February 2024 Edzelco talk contribs created page Lutetium (177Lu) vipivotide tetraxetan (Created page with "{{DrugProjectFormSinglePage |genericName=lutetium (177Lu) vipivotide tetraxetan |aOrAn=a |drugClass=radioligand therapeutic agent |indicationType=treatment |indication=adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy |adverseReactions=fatigue, dry mout...")
- 00:44, 7 February 2024 Edzelco talk contribs created page File:Pluvicto label.png
- 00:44, 7 February 2024 Edzelco talk contribs uploaded File:Pluvicto label.png
- 00:44, 7 February 2024 Edzelco talk contribs created page File:Pluvicto structure.png
- 00:44, 7 February 2024 Edzelco talk contribs uploaded File:Pluvicto structure.png
- 00:57, 6 February 2024 Edzelco talk contribs created page Nivolumab and relatlimab-rmbw (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=nivolumab and relatlimab-rmbw |aOrAn=a |drugClass=combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody |indicationType=treatment |indication=adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma |adverseReactions=immune-mediated pneumonitis, im...")
- 00:56, 6 February 2024 Edzelco talk contribs created page File:Nivolumab and relatlimab-rmbw label.png
- 00:56, 6 February 2024 Edzelco talk contribs uploaded File:Nivolumab and relatlimab-rmbw label.png
- 00:22, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone bottle carton.png
- 00:22, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone bottle carton.png
- 00:22, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone bottle suspension label 50mg.png
- 00:22, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone bottle suspension label 50mg.png
- 00:21, 6 February 2024 Edzelco talk contribs created page File:Ganaloxone structure.png
- 00:21, 6 February 2024 Edzelco talk contribs uploaded File:Ganaloxone structure.png
- 15:47, 2 February 2024 Edzelco talk contribs created page Pacritinib (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Pacritinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L (1) |adverseReactions=diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema |fdaLIADAdult=The recommended dosage of VONJO is 200 mg orally twi...")
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib Bottle Label.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib Bottle Label.png
- 15:47, 2 February 2024 Edzelco talk contribs created page File:Pacritinib Carton Label.png
- 15:47, 2 February 2024 Edzelco talk contribs uploaded File:Pacritinib Carton Label.png
